投资价值获得国际资本市场的权威认可。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据 IPO早知道消息，晶泰科技（ 2228.HK ）于 8月27日发布了截至2025年6月30日止六个月的业 绩公告。 财报显示，晶泰科技 上半年 营收 5.17亿元，同比增长403.8%。其中， 药物发现解决方案业务收 入 同比 增长 615.2%至 4.35亿元； 智能机器人解决方案业务收入 同比增长 95.9%至 0.82亿元 值得一提的是， 晶泰科技在今年上半年首次实现半年盈利，上半年的 经调整净利润 为 1.42亿元 。 截至 2025年6月30日，晶泰科技持有现金余额53.08亿元，现金储备较为充裕。 此外， 晶泰科技于今年 5月已获纳入 MSCI中国 小型 股指数 并已生效，这也 标志着 其 投资价值 获得国际资本市场的权威认可 。 截至 8月27日，晶泰科技的市值超412亿港元，是目前 亚洲 AI药物发现领域市值最高 的企业；同 时，晶泰科技也是 全球 AI药物研发领域历史融资规模最大的公司，曾创下AI药物研发领域融资额的 最高纪录 。 | 序号 | 证券中文简称 | ...

日前，晶泰控股(02228.HK)公布了截至2025年6月30日止6个月的业绩，下面将通过一图看懂晶泰控股 (02228.HK)2025H1业绩。 业绩摘要 ▶ 上市一年来首次实现半年盈利,这一里程碑凝聚着公司全体 伙伴的智慧与协同创新,更标志着企业已迈入规模化发展的全 新增长阶段,为未来战略蓝图奠定了更加坚实基础。 上半年营收 T 百万元 同比增长403.8%1 上半年经调整净利润 现金余额 141.6 万元 5,307.7 百万元 业务回顾 02 (s) 药物发现解决方案:最强AI大脑与机器人技术 深度融合,驱动药物研发业务进入新阶段 01 435.2 单位:百万元 报告期内,药物发现解决方案 业务收入实现非常强劲的增长 60.9 615.2% 这一增长主要得益于重大合作获 得了可观的首付款,及多条管线成 功达到相应里程碑 2024年上半年 2025年上半年 -- 1 与生物制药传奇 Gregory Verdine 教授达成重大合作 协议包含第一阶段首付款 有权获得的进一步付款 5,100万美元 4、900万美元 有资格获得的潜在监管里程碑及商业里程碑付款 58.9亿美元 以及基于产品年度净销售额的潜在个 ...

于报告期末，公司现金余额合计53.08亿元，财务状况良好，公司上半年月均现金消耗降低20.0%至4970 万元，上半年经调整净利润为1.42亿元，首次实现半年盈利，这一里程碑凝聚着公司的智慧与协同创 新，更标志着企业已迈入规模化发展的全新增长阶段，为未来战略蓝图奠定了更加坚实的基础。 公告称，于报告期间，药物发现解决方案业务收入实现非常强劲的增长，从截至2024年6月30日止六个 月的6090万元增长615.2%至截至2025年6月30日止六个月4.35亿元。这一增长主要得益于集团与 DoveTree Medicines LLC及其联属公司(DoveTree)开展重大合作。集团达成了该项合作的第一阶段里程 碑并收到首付款5100万美元。此外，集团抗体业务产生的收入亦表现出强劲增长。 晶泰控股(02228)发布截至2025年6月30日止六个月的中期业绩，收入5.17亿元(人民币，下同)，同比增 加403.83%;股东应占溢利8279.5万元，上年同期股东应占亏损12.37亿元，同比扭亏为盈;每股基本盈利 1.51分。 ...

于报告期间，药物发现解决方案业务收入实现非常强劲的增长，从截至2024年6月30日止六个月的人民 币60.9百万元增长615.2%至截至2025年6月30日止六个月人民币435.2百万元。这一增长主要得益于集团 与DoveTree Medicines LLC及其联属公司开展重大合作。公司达成了该项合作的第一阶段里程碑并收到 首付款51百万美元。 此外，公司抗体业务产生的收入亦表现出强劲增长。于报告期间，智能机器人解决方案业务收入实现高 速增长，从截至2024年6月30日止六个月的人民币41.8百万元增长95.9%至截至2025年6月30日止六个月 的人民币81.9百万元。主要由自动化化学合成服务及XtaPi研发解决方案的高速增长驱动。 公司相信，科学研发的未来，蕴育在人工智能、具身智能与人类智慧的深度融合里。公司正破题攻坚开 拓未来，化技术瓶颈为破局契机，变天马行空为惠世良方，构筑生命科学与材料科学领域的超级人工智 能。用科研新范式重塑人类文明新图景。 格隆汇8月27日丨晶泰控股(02228.HK)发布2025年上半年财务业绩，上半年集团实现营业收入人民币 517.1百万元，同比增长403.8%。于报告期末， ...

公告称，于报告期间，药物发现解决方案业务收入实现非常强劲的增长，从截至2024年6月30日止六个 月的6090万元增长615.2%至截至2025年6月30日止六个月4.35亿元。这一增长主要得益于集团与 DoveTree Medicines LLC及其联属公司(DoveTree)开展重大合作。集团达成了该项合作的第一阶段里程 碑并收到首付款5100万美元。此外，集团抗体业务产生的收入亦表现出强劲增长。 于报告期末，公司现金余额合计53.08亿元，财务状况良好，公司上半年月均现金消耗降低20.0%至4970 万元，上半年经调整净利润为1.42亿元，首次实现半年盈利，这一里程碑凝聚着公司的智慧与协同创 新，更标志着企业已迈入规模化发展的全新增长阶段，为未来战略蓝图奠定了更加坚实的基础。 智通财经APP讯，晶泰控股(02228)发布截至2025年6月30日止六个月的中期业绩，收入5.17亿元(人民 币，下同)，同比增加403.83%;股东应占溢利8279.5万元，上年同期股东应占亏损12.37亿元，同比扭亏 为盈;每股基本盈利1.51分。 ...

Group 1 - The core point of the news is that Crystal Tech Holdings has signed a final agreement with DoveTree Medicines LLC, receiving an initial payment of $51 million and being eligible for additional payments totaling $4.9 million, as well as potential milestone payments up to $5.89 billion and royalties based on annual net sales [1][3] - The agreement allows Crystal Tech Holdings to utilize its AI and robotics-based drug discovery platform to develop multiple small molecule and antibody candidates targeting oncology, immunology, inflammation, neurological disorders, and metabolic disorders for DoveTree, which will have exclusive global development and commercialization rights [1][3] - Following this significant news, Crystal Tech Holdings' stock price surged by 15% on August 6, with its market capitalization exceeding HKD 30 billion [1] Group 2 - From a financial perspective, Crystal Tech Holdings has shown a gradual increase in revenue from 2021 to 2024, with revenues of 62.8 million, 133 million, 174 million, and 266 million respectively, despite incurring losses of 2.137 billion, 1.439 billion, 1.906 billion, and 1.514 billion during the same period [2] - The adjusted net loss figures for the same years were 271 million, 437 million, 522 million, and 457 million [2] - The company's business is primarily divided into two segments: intelligent robotics solutions and drug discovery solutions, with intelligent robotics solutions showing remarkable performance in 2024, achieving revenue of 163 million, a year-on-year increase of 87.8%, becoming the main driver of revenue growth [2]

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expectation of stock price appreciation exceeding 15% over the next six months [6]. Core Insights - The company is entering a new phase of commercialization with projected revenue of 266.43 million yuan in 2024, representing a year-on-year increase of 52.8%, driven by significant growth in intelligent robotics and drug discovery solutions [1][2]. - The company has achieved a substantial reduction in net losses, with an adjusted net loss of 4.57 billion yuan in 2024, narrowing by 12.5% year-on-year, and is expected to turn profitable as revenue scales up [1][3]. - The company has a robust cash reserve of 31.23 billion yuan as of December 31, 2024, which, when combined with additional funds from recent placements, is projected to support operations for the next decade [1]. Summary by Sections Revenue and Growth - In 2024, the company expects to achieve revenue of 266.43 million yuan, a 52.75% increase from the previous year, with significant contributions from intelligent robotics (up 87.8%) and drug discovery solutions (up 18.2%) [1][5]. - The company has diversified its client base, serving 16 of the top 20 global biotechnology and pharmaceutical companies, which has contributed to the growth in its drug discovery revenue [2]. Strategic Partnerships and Acquisitions - The company has entered into strategic partnerships with major pharmaceutical firms such as Johnson & Johnson and has acquired 90% of the shares in Siwei Medical for 250 million yuan, enhancing its capabilities in AI medical applications [2][3]. - The company has established a five-year strategic R&D cooperation agreement with GCL Group to develop AI perovskite materials, positioning itself in the AI new materials sector [3]. Financial Projections - The company forecasts revenues of 424.07 million yuan, 676.38 million yuan, and 1.08 billion yuan for 2025, 2026, and 2027, respectively, with corresponding price-to-sales ratios of 52.83X, 33.14X, and 20.72X [3][5]. - The report anticipates a gradual improvement in profitability, with net losses expected to decrease significantly over the next few years, potentially achieving a net profit of 70.36 million yuan by 2027 [5].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Viewpoints - The company is positioned as a rare asset in the AI for Science sector, aiming to disrupt traditional R&D paradigms and unlock significant market potential [1][14]. - The company has achieved a revenue milestone that qualifies it as a commercial entity under Hong Kong Stock Exchange rules, with a notable reduction in net losses [8][14]. - The integration of dry and wet lab experiments creates a data barrier that strengthens the company's competitive moat [8][14]. - The company is making progress in its collaborative drug pipeline and expanding its client base in new materials and other sectors [8][14]. - Short-term growth is driven by policy incentives, while long-term growth is supported by customer retention and successful project incubation [8][14]. Summary by Sections 1. AI for Science as a Rare Asset - The company, founded in 2015, leverages quantum physics and AI to provide innovative R&D solutions across pharmaceuticals and materials science [14]. - The founding team consists of MIT-trained scientists, enhancing the company's R&D capabilities [8][14]. - The company has raised approximately $732 million from global investors, establishing itself as a leader in AI-enabled drug discovery [17][19]. 2. AI Solutions and Automation Industry - The AI solutions market is expected to grow significantly, particularly in healthcare and materials science [26][30]. - The global automation market is rapidly expanding, with laboratory automation penetration projected to increase from 3.7% in 2022 to 23.2% by 2030 [27][30]. - The convergence of data growth, labor cost increases, and technological integration is driving the growth of AI solutions and automation [34]. 3. Revenue and Profitability Forecast - The company forecasts revenues of RMB 4.26 billion, RMB 6.83 billion, and RMB 10.95 billion for 2025, 2026, and 2027, respectively, with a projected return to profitability by 2027 [1][8]. - The adjusted net loss is expected to narrow significantly over the forecast period, indicating improving financial health [1][8]. 4. Market Trends and Opportunities - The AI drug discovery market is anticipated to grow from RMB 2.76 billion in 2022 to RMB 67.7 billion by 2025, driven by advancements in technology and increased collaboration [41][42]. - The solid-state R&D services market is projected to grow at a CAGR of 27.7%, reaching $20.9 billion by 2030 [52].